Jonathan E. Rosenberg, MD, discusses what the frontline treatment landscape for metastatic urothelial cancer currently looks like.
Jonathan E. Rosenberg, MD, chief of Genitourinary Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses what the frontline treatment landscape for metastatic urothelial cancer currently looks like.
According to Rosenberg, patients who are cisplatin eligible, experts recommend a cisplatin-based combination chemotherapy of either gemcitabine and cisplatin, or dose-dense MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin). Cisplatin ineligible patients are likely to be given gemcitabine and carboplatin, then maintenance nivolumab (Opdivo).
A treatment option for patients not eligible for any platinum chemotherapy, or for those with multiple comorbidities, is checkpoint inhibitor monotherapy with either atezolizumab (Tecentriq) or pembrolizumab (Keytruda).
Transcription:
0:08 | Today, there are several treatment options for patients with metastatic urothelial cancer who have not yet received prior therapy. For patients who are cisplatin candidates, cisplatin-based combination chemotherapy is the standard. Either gemcitabine and cisplatin or dose-dense MVAC are the 2 options.
0:23 | For patients who are cisplatin ineligible, gemcitabine and carboplatin followed by maintenance nivolumab, if they respond, is the most common option for PD-L1–positive patients in the United States. Atezolizumab is an option as well.
0:38 | For those patients who are not eligible for any platinum chemotherapy or people who have multiple comorbidities, checkpoint inhibitor monotherapy with either atezolizumab or pembrolizumab are both possible treatment choices for those patients
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More